The Tumor Necrosis Factor-α Level in Platelet-Rich Plasma Might Be Associated with Treatment Outcome in Patients with Interstitial Cystitis/Bladder Pain Syndrome or Recurrent Urinary Tract Infection

IF 4.9 2区生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

International Journal of Molecular Sciences Pub Date : 2023-12-21 DOI:10.3390/ijms25010163

J. Jhang, Yuan-Hong Jiang, Teng-Yi Lin, H. Kuo

{"title":"The Tumor Necrosis Factor-α Level in Platelet-Rich Plasma Might Be Associated with Treatment Outcome in Patients with Interstitial Cystitis/Bladder Pain Syndrome or Recurrent Urinary Tract Infection","authors":"J. Jhang, Yuan-Hong Jiang, Teng-Yi Lin, H. Kuo","doi":"10.3390/ijms25010163","DOIUrl":null,"url":null,"abstract":"Using platelet-rich plasma (PRP) injections to treat urological diseases has attracted great attention. This study investigated the impact of cytokine concentrations in PRP on the treatment outcome of patients with recurrent urinary tract infection (rUTI) and interstitial cystitis/bladder pain syndrome (IC/BPS). Forty patients with IC/BPS and twenty-one patients with rUTI were enrolled for four-monthly repeated PRP injections. PRP was collected at the first injection and analyzed with multiplex immunoassays for 12 target cytokines. In patients with IC/BPS, a Global Response Assessment (GRA) score ≥ 2 was defined as a successful outcome. In rUTI patients, ≤2 episodes of UTI recurrence during one year of follow-up was considered a successful outcome. Nineteen (47.5%) patients with IC/BPS and eleven (52.4%) patients with rUTI had successful outcomes. The IC/BPS patients with successful outcomes had significantly lower levels of tumor necrosis factor-α (TNF-α) in their PRP than those with unsuccessful outcomes (p = 0.041). The rUTI patients with successful outcomes also had a lower level of TNF-α (p = 0.025) and a higher level of epidermal growth factor (p = 0.035) and transforming growth factor-β2 (p = 0.024) in PRP than those with unsuccessful outcomes. A lower level of TNF-α in PRP might be a potentially predictive factor of treatment outcome.","PeriodicalId":49179,"journal":{"name":"International Journal of Molecular Sciences","volume":"135 31","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Molecular Sciences","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3390/ijms25010163","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Using platelet-rich plasma (PRP) injections to treat urological diseases has attracted great attention. This study investigated the impact of cytokine concentrations in PRP on the treatment outcome of patients with recurrent urinary tract infection (rUTI) and interstitial cystitis/bladder pain syndrome (IC/BPS). Forty patients with IC/BPS and twenty-one patients with rUTI were enrolled for four-monthly repeated PRP injections. PRP was collected at the first injection and analyzed with multiplex immunoassays for 12 target cytokines. In patients with IC/BPS, a Global Response Assessment (GRA) score ≥ 2 was defined as a successful outcome. In rUTI patients, ≤2 episodes of UTI recurrence during one year of follow-up was considered a successful outcome. Nineteen (47.5%) patients with IC/BPS and eleven (52.4%) patients with rUTI had successful outcomes. The IC/BPS patients with successful outcomes had significantly lower levels of tumor necrosis factor-α (TNF-α) in their PRP than those with unsuccessful outcomes (p = 0.041). The rUTI patients with successful outcomes also had a lower level of TNF-α (p = 0.025) and a higher level of epidermal growth factor (p = 0.035) and transforming growth factor-β2 (p = 0.024) in PRP than those with unsuccessful outcomes. A lower level of TNF-α in PRP might be a potentially predictive factor of treatment outcome.

查看原文本刊更多论文

富血小板血浆中的肿瘤坏死因子-α水平可能与间质性膀胱炎/膀胱疼痛综合征或复发性尿路感染患者的治疗效果有关

利用富血小板血浆（PRP）注射治疗泌尿系统疾病已引起广泛关注。本研究调查了血小板富集血浆中细胞因子浓度对复发性尿路感染（rUTI）和间质性膀胱炎/膀胱疼痛综合征（IC/BPS）患者治疗效果的影响。40名IC/BPS患者和21名复发性尿路感染患者参加了为期四个月的PRP重复注射。在第一次注射时收集 PRP，并用多重免疫测定法分析 12 种目标细胞因子。在 IC/BPS 患者中，全球反应评估 (GRA) 评分≥ 2 分即为成功。在 rUTI 患者中，随访一年期间UTI 复发次数≤2 次即为成功。19名（47.5%）IC/BPS 患者和 11 名（52.4%）rUTI 患者获得了成功结果。成功治愈的 IC/BPS 患者 PRP 中肿瘤坏死因子-α（TNF-α）的水平明显低于失败治愈的患者（p = 0.041）。与治疗失败的患者相比，治疗成功的 rUTI 患者的 PRP 中 TNF-α 水平较低（p = 0.025），表皮生长因子（p = 0.035）和转化生长因子-β2（p = 0.024）水平较高。PRP中较低水平的TNF-α可能是治疗结果的潜在预测因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Molecular Sciences Chemistry-Organic Chemistry

CiteScore

8.10

自引率

10.70%

发文量

13472

审稿时长

17.49 days

期刊介绍： The International Journal of Molecular Sciences (ISSN 1422-0067) provides an advanced forum for chemistry, molecular physics (chemical physics and physical chemistry) and molecular biology. It publishes research articles, reviews, communications and short notes. Our aim is to encourage scientists to publish their theoretical and experimental results in as much detail as possible. Therefore, there is no restriction on the length of the papers or the number of electronics supplementary files. For articles with computational results, the full experimental details must be provided so that the results can be reproduced. Electronic files regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material (including animated pictures, videos, interactive Excel sheets, software executables and others).